Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial

Preliminary data suggest promising activity of loncastuximab tesirine in follicular lymphoma, and synergistic activity between rituximab-induced cytotoxicity and loncastuximab tesirine. In this study, we evaluated loncastuximab tesirine combined with rituximab for second-line and later treatment of...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The Lancet. Haematology Ročník 12; číslo 1; s. e23
Hlavní autori:	Alderuccio, Juan Pablo, Alencar, Alvaro J, Schatz, Jonathan H, Kuker, Russ A, Pongas, Georgios, Reis, Isildinha M, Lekakis, Lazaros J, Spiegel, Jay Y, Sandoval-Sus, Jose, Beitinjaneh, Amer, Stanchina, Michele D, Trabolsi, Asaad, Lossos, Izidore S, Rosenblatt, Joseph D, Lessen, David S, Moskowitz, Craig H
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England 01.01.2025
Predmet:	Adult Aged Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Benzodiazepines Female Humans Immunoconjugates - adverse effects Immunoconjugates - therapeutic use Lymphoma, Follicular - drug therapy Male Middle Aged Neoplasm Recurrence, Local - drug therapy Rituximab - administration & dosage Rituximab - adverse effects Rituximab - therapeutic use
ISSN:	2352-3026, 2352-3026
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!